Literature DB >> 10646769

Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor.

D H Rowe1, J Huang, M L Kayton, R Thompson, A Troxel, K M O'Toole, D Yamashiro, C J Stolar, J J Kandel.   

Abstract

BACKGROUND/
PURPOSE: Vascular endothelial growth factor (VEGF) has been shown previously to correlate with tumor growth and metastasis in an experimental model of anaplastic Wilms' tumor. The authors hypothesized that treatment with anti-VEGF antibodies would suppress both primary tumor growth and metastasis in this model.
METHODS: Tumors were induced in the right kidneys of nude mice by the injection of cultured Wilms' tumor cells. After 1 week, anti-VEGF treatment was begun with injection of either vehicle or an anti-VEGF antibody intraperitoneally. Mice were killed after 4.5 weeks of treatment and tumor weights and the incidence of metastases evaluated.
RESULTS: Anti-VEGF treatment resulted in a greater than 95% reduction in tumor weight (P < .0001). Anti-VEGF treatment also abolished the establishment of lung metastases (40% in control animals, P < .003). Cessation of treatment resulted in rebound tumor growth.
CONCLUSION: Anti-VEGF therapy can suppress both primary tumor growth and the establishment of metastases in experimental anaplastic Wilms' tumor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646769     DOI: 10.1016/s0022-3468(00)80008-1

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  25 in total

1.  Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors.

Authors:  Shashank R Sirsi; Sonia L Hernandez; Lukasz Zielinski; Henning Blomback; Adel Koubaa; Milo Synder; Shunichi Homma; Jessica J Kandel; Darrell J Yamashiro; Mark A Borden
Journal:  J Control Release       Date:  2011-09-17       Impact factor: 9.776

2.  Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.

Authors:  Shashank R Sirsi; Molly L Flexman; Fotois Vlachos; Jianzhong Huang; Sonia L Hernandez; Hyun Keol Kim; Tessa B Johung; Jeffrey W Gander; Ari R Reichstein; Brooke S Lampl; Antai Wang; Andreas H Hielscher; Jessica J Kandel; Darrell J Yamashiro; Mark A Borden
Journal:  Ultrasound Med Biol       Date:  2012-03-16       Impact factor: 2.998

Review 3.  Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

Authors:  Katrien De Bock; Massimiliano Mazzone; Peter Carmeliet
Journal:  Nat Rev Clin Oncol       Date:  2011-05-31       Impact factor: 66.675

Review 4.  Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.

Authors:  Julia Glade Bender; Darrell J Yamashiro; Elizabeth Fox
Journal:  Oncologist       Date:  2011-10-31

5.  Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Authors:  Leo Mascarenhas; Yueh-Yun Chi; Pooja Hingorani; James R Anderson; Elizabeth R Lyden; David A Rodeberg; Daniel J Indelicato; Simon C Kao; Roshni Dasgupta; Sheri L Spunt; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2019-09-12       Impact factor: 44.544

6.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

Authors:  Eugene S Kim; Anna Serur; Jianzhong Huang; Christina A Manley; Kimberly W McCrudden; Jason S Frischer; Samuel Z Soffer; Laurence Ring; Tamara New; Stephanie Zabski; John S Rudge; Jocelyn Holash; George D Yancopoulos; Jessica J Kandel; Darrell J Yamashiro
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

7.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

Review 8.  Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

Authors:  Margaret E Macy; Kelly K Sawczyn; Timothy P Garrington; Douglas K Graham; Lia Gore
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

9.  Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma.

Authors:  M A Ghanem; G J van Steenbrugge; M K Sudaryo; R B Mathoera; J M Nijman; Th H van der Kwast
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

10.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

Authors:  H Wildiers; G Guetens; G De Boeck; E Verbeken; B Landuyt; W Landuyt; E A de Bruijn; A T van Oosterom
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.